Is AOD-9604 Legal in New York? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic peptide fragment derived from amino acids 176 to 191 of human growth hormone. Researchers originally investigated it as a lipolytic agent, hypothesizing that this C-terminal fragment could stimulate fat breakdown without the mitogenic or insulin-desensitizing effects of full-length growth hormone. Those early mechanistic findings generated significant commercial interest, but the compound never cleared the bar required for FDA drug approval.

The Failed Approval History

Metabolic Pharmaceuticals Ltd. Conducted Phase II and Phase III clinical trials for AOD-9604 as an oral obesity treatment in the early 2000s. The trials did not demonstrate sufficient efficacy to support a New Drug Application (NDA), and the company did not proceed to FDA approval. Without an approved NDA or Abbreviated NDA (ANDA), AOD-9604 has no legal drug status in the United States under the Federal Food, Drug, and Cosmetic Act (FD&C Act) [1].

Why Federal Status Controls New York Practice

New York's public health law and the regulations of the New York State Board of Pharmacy incorporate federal drug law by reference. A substance that lacks federal approval or a recognized compounding pathway cannot be dispensed to patients in New York regardless of what any individual practitioner believes about its safety profile. The FDA's authority over drug approval is national, and state medical boards cannot override it [2].

The FDA Compounding Framework: 503A and 503B Explained

Compounding pharmacies in the United States operate under two primary federal pathways. Section 503A of the FD&C Act governs traditional compounding pharmacies that prepare patient-specific prescriptions. Section 503B governs outsourcing facilities that may produce larger batches for office use. Both pathways come with explicit restrictions on which bulk drug substances may be used [3].

The Bulks Nomination and Evaluation Process

The FDA maintains a "Bulks List" for each pathway. Nominated substances are evaluated by the Pharmacy Compounding Advisory Committee (PCAC) against criteria including: whether a clinical need exists that cannot be met by an approved drug, the substance's safety and efficacy data, and whether the ingredient is a component of an FDA-approved drug [4].

AOD-9604 was nominated for inclusion on the 503A bulks list as a substance that pharmacies wished to compound. The FDA reviewed the nomination and did not place AOD-9604 on the list of substances that may be used in compounding. Substances that are not on the affirmative "may use" list are prohibited from compounding under both 503A and 503B [3].

What This Means in Practice

A licensed compounding pharmacy in New York that prepares AOD-9604 injectable vials for patient use is violating federal law. The FDA has broad enforcement authority and may issue warning letters, seek injunctions, or refer cases to the Department of Justice. The New York State Board of Pharmacy may separately sanction a pharmacist's license for dispensing an unapproved drug product outside the legal compounding framework [5].

New York State Pharmacy and Medical Practice Regulations

New York does not have a state-specific peptide statute that carves out AOD-9604. The relevant state-level rules are the New York Education Law Article 137 (pharmacy practice) and Article 131 (medical practice), both of which prohibit prescribing or dispensing drugs that are not approved or otherwise authorized under federal law.

New York Board of Pharmacy Standards

The New York State Board of Pharmacy requires compounding pharmacies to follow USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile) standards. Those USP chapters govern the process of compounding but do not authorize the compounding of federally prohibited substances [6]. A pharmacy operating under a New York license that compounds AOD-9604 injectables risks both federal enforcement and state license revocation.

Physician Prescribing Authority in New York

New York physicians hold broad prescribing authority under state law, but that authority does not extend to unapproved substances outside of specific exemptions such as FDA-sanctioned investigational new drug (IND) protocols. Writing a prescription for AOD-9604 to be dispensed by a pharmacy is not protected by off-label prescribing doctrine. Off-label prescribing applies to FDA-approved drugs used for non-approved indications; AOD-9604 has no approved indication at all [2].

The table below summarizes the legal pathway analysis a HealthRX clinician applies when a patient requests AOD-9604 in New York.

| Legal Question | Applicable Rule | AOD-9604 Answer | |---|---|---| | Is it FDA-approved? | FD&C Act Section 505 | No | | Is it on the 503A bulks "may use" list? | 21 CFR Part 216 | No | | Is it on the 503B bulks "may use" list? | FD&C Act Section 503B | No | | Can a NY physician prescribe off-label? | Off-label doctrine | No (requires an approved drug) | | Can a NY compounding pharmacy prepare it? | NY Ed. Law Art. 137 + federal | No | | Is a research-chemical purchase legal for personal use? | FD&C Act / DEA regs | Gray area; not for human administration |

Research Chemical Gray Area: What "For Research Use Only" Actually Means

Online vendors sell AOD-9604 labeled "for research use only" or "not for human consumption." This labeling is not a legal shield for the buyer or the seller when the product is intended for human use. The FDA has stated clearly in multiple warning letters that labeling a peptide as a research chemical does not exempt it from the FD&C Act's drug provisions if the seller or buyer intends it for human administration [7].

Risks of Gray-Market AOD-9604

Peptide products sourced outside of a licensed U.S. Pharmacy carry documented quality risks. A 2018 analysis published by Brennan and colleagues found that a substantial proportion of research-grade peptides purchased online contained incorrect concentrations, bacterial endotoxins, or degradation products inconsistent with their labels [8]. Injecting an impure peptide carries infection risk, immune reaction risk, and the risk of unknown pharmacological effects from contaminants.

No Safe "Personal Use" Importation Pathway

Some consumers believe that importing small quantities of AOD-9604 from overseas peptide suppliers falls under FDA's personal importation policy. The FDA's personal importation guidance covers FDA-approved drugs not available in the United States or drugs available at lower cost abroad. It does not cover unapproved drugs or research chemicals intended for self-administration [9]. Packages containing AOD-9604 labeled for human use may be seized at U.S. Customs.

Clinical Trial Access: The One Legal Pathway for Human Use

Participation in an IRB-approved clinical trial that holds an active IND from the FDA is the only legal route through which a New York resident could receive AOD-9604 as a human subject. Under an IND, an investigational drug may be administered to participants under informed consent and physician supervision [10].

How to Search for Active Trials

ClinicalTrials.gov, operated by the National Library of Medicine, lists all registered interventional studies in the United States. As of the date of this article's review, no active Phase II or Phase III trials of AOD-9604 were listed with U.S. Enrollment sites. Interested patients may monitor ClinicalTrials.gov directly for future registrations [11].

Expanded Access (Compassionate Use)

The FDA's expanded access program allows individual patients with serious conditions to receive investigational drugs outside of a clinical trial if a manufacturer holds an IND and agrees to provide the drug. No manufacturer currently holds an active IND for AOD-9604 in the United States that is publicly listed, making expanded access effectively unavailable [10].

FDA-Approved Alternatives for Weight Management in New York

Because the primary clinical interest in AOD-9604 centers on fat loss and body composition, patients and clinicians should consider the approved agents that have demonstrated efficacy in controlled trials.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management in June 2021. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [12]. The FDA label specifies use in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [13].

Tirzepatide 2.5 mg to 15 mg (Zepbound) received FDA approval for weight management in November 2023. The SURMOUNT-1 trial (N=2,539) showed a mean weight reduction of 20.9% at the 15 mg dose versus 3.1% for placebo at 72 weeks [14].

Growth Hormone Secretagogues With a Clearer Regulatory Pathway

Tesamorelin (Egrifta), a GHRH analogue, is FDA-approved for lipodystrophy in HIV-infected patients. Sermorelin holds compounding eligibility under certain circumstances. Neither is equivalent to AOD-9604, but both represent peptide-class options that exist within a defined legal framework. Any prescribing decision should occur under direct physician supervision following a complete medical evaluation [15].

The FDA's Guidance on Unapproved Drugs

The FDA's Compliance Policy Guide (CPG) Sec. 440.100 states: "FDA-approved drugs are required to be safe and effective. FDA pursues regulatory action against unapproved new drugs that present safety risks or that lack evidence of effectiveness" [7]. This applies directly to AOD-9604 marketed for human use.

What New York Patients Should Do Instead

Patients in New York who are interested in peptide-based therapies for weight loss or body composition have several concrete steps available.

Step 1: Consult a Board-Certified Physician

A physician who is board-certified in endocrinology, obesity medicine, or internal medicine can assess whether a GLP-1 agonist or other FDA-approved agent is appropriate. The Obesity Medicine Association and the American Association of Clinical Endocrinologists (AACE) both publish evidence-based treatment algorithms. The 2023 AACE Clinical Practice Guidelines for obesity state that pharmacotherapy should be initiated alongside lifestyle intervention in patients meeting BMI criteria [16].

Step 2: Ask About Compounded Semaglutide or Tirzepatide (Where Available)

During periods of FDA-documented drug shortage, 503A and 503B pharmacies may compound copies of FDA-approved drugs. The FDA has issued guidance on which conditions must be met. This is not equivalent to accessing AOD-9604 but may offer a cost-accessible route to an approved active ingredient under legal compounding conditions [3].

Step 3: Report Vendors Selling AOD-9604 for Human Use

The FDA MedWatch program and the FDA's Office of Criminal Investigations accept reports of suspected illegal drug sales. Reporting vendors who sell AOD-9604 with human-use labeling protects other consumers and supports enforcement [17].

A Direct Note on Telehealth Platforms Advertising AOD-9604

Multiple telehealth platforms have marketed AOD-9604 injectable kits to patients in New York and other states. As of the FDA's November 2023 guidance update on bulk drug substances, no U.S.-licensed telehealth platform has a legal basis for prescribing AOD-9604 for patient dispensing. Patients who have received such prescriptions should discuss their situation with a licensed physician. The FDA's MedWatch adverse event reporting system is available for any adverse outcomes experienced from peptides obtained through these channels [17].

The American Society of Health-System Pharmacists (ASHP) policy statement on compounding notes: "Pharmacists should not compound preparations that are copies of commercially available products or that contain ingredients that are not safe and effective" [6]. AOD-9604 falls outside the safe harbor those guidelines describe.